CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2024

Dec 12, 2024

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	8 April 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest		Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevantinterest.		Director related parties
Date of change		(a) 9 December 2024 (b) 10 December 2024 (c) 13 December 2024
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	1,232,142	-
		Indirect	93,762,432	-
		Total	94,994,574	-
Class		(a) Ordinary shares (b),(c) CHMAYunlisted options
Number acquired				Options 31,580,882 80,000,000 **111,580,882 **
			Shares	Options
		Direct	20,000,000	31,580,882
		Indirect	80,000,000	80,000,000
		**Total **	100,000,000	**111,580,882 **
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		(a) A$0.008 per ordinary share (b),(c) Nil consideration for unlisted options	(a) A$0.008 per ordinary share (b),(c) Nil consideration for unlisted options	(a) A$0.008 per ordinary share (b),(c) Nil consideration for unlisted options
No. of securities held after change				Options 31,580,882 80,000,000 111,580,882
			Shares	Options
		Direct	21,232,142	31,580,882
		Indirect	173,762,432	80,000,000
		Total	194,994,574	111,580,882
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		(a),(c) Participation in Placement approved @ EGM 4 December 2024 (100,000,000 ordinary shares and 100,000,000 unlisted options) (b) Unlisted options issued under the Company’s Omnibus Incentive Plan. approved @AGM 12November 2024

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relationtowhichtheinteresthas changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3